Lack of evidence for increased inhibitor incidence in patients switched from plasma-derived to recombinant factor VIII

Haemophilia

Volumn 7, Issue 4, 2001, Pages 346-348

  Scharrer, I ^a   Ehrlich, H J ^b  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b BAXTER INNOVATIONS GMBH   (Austria)

Author keywords

Blood coagulation factor inhibitors; Clinical trials; Factor VIII; Haemophilia A; Incidence; Recombinant proteins

Indexed keywords

BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 8 DERIVATIVE; BLOOD CLOTTING FACTOR 8 INHIBITOR; RECOMBINANT BLOOD CLOTTING FACTOR 8; REPLENATE;

BLOOD TRANSFUSION; CLINICAL STUDY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EXPOSURE; DRUG SAFETY; HEMOPHILIA A; HUMAN; HUMAN TISSUE; IMMUNOSURVEILLANCE; INCIDENCE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT;

ANTIBODIES; FACTOR VIII; HEMOPHILIA A; HUMANS; RECOMBINANT PROTEINS;

EID: 0034917039     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2001.00515.x     Document Type: Review

References (17)

1. Incidence of inhibitors in haemophilia A patients - A review of recent studies of recombinant and plasma-derived factor VIII concentrates
2. A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate
3. A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in the Netherlands
4. Factor VIII inhibitors in previously treated haemophilia A patients with a double virus-inactivated plasma derived factor VIII concentrate
5. Is a change of factor VIII product a risk factor for the development of a factor VIII inhibitor?
6. Comparison of high responder inhibitor frequency in recent studies of previously untreated patients with hemophilia A
7. Experiences with recombinant factor VIII products: Development of inhibitors and immune tolerance therapy
8. Frequent but low titre factor VIII inhibitors in haemophilia A patients treated with high purity concentrates
9. Is a change of factor VIII product a risk factor for the development of a factor VIII inhibitor?
10. Inhibitor development in a multitransfused patient with severe haemophilia A
11. High responding factor VIII inhibitors in mild haemophilia - Is there a link with recent changes in clinical practice?
12. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A
13. A multicenter pharmacosurveillance study for the evaluation of the efficacy and safety of recombinant factor VIII in the treatment of patients with hemophilia A
14. Second generation, B-domain deleted recombinant factor VIII
15. A multicenter study of recombinant factor VIII (Recombinate™) in previously treated patients with hemophilia A
16. Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy: Results of a multicenter, international, clinical investigation
17. Surveillance for factor VIII inhibitor development in the Canadian hemophilia A population following the widespread introduction of recombinant factor VIII replacement therapy